Solventum Corporation
$84.50-$1.30 (-1.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $14.3B
- P/E
- 9.2x
- EV / EBITDA
- 7.2x
- Revenue
- $8.3B
- Net margin
- 18.7%
- ROCE
- 5.7%
Price chart
Technical chartScreen technicals →+6.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -2.2%
- 3M
- -4.6%
- 6M
- +11.0%
- 1Y
- +6.3%
- 5Y
- Short history
- A period is left blank when the price history is shorter than the period.
52-week range
Day change -$1.30 (-1.5%) from $86 to $85 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in SOLV, bought on each weekday since 2024.
News & filings
What Solventum filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernOperating cash flow was 0.24 times net profit in fiscal 2025.
Strengths (1)
- EBITDA grew 66.9% in fiscal 2025, 66.1 points more than revenue.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Read moreShow less
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
- Sector
- Healthcare
- Shares outstanding
- 174.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $14.3B
- P/E
- 9.2x
- P/B
- 2.8x
- EV / EBITDA
- 7.2x
- EV / Sales
- 2.2x
- P/S
- 1.7x
- 52-week high
- $92.44
- 52-week low
- $62.49
Profitability
- Operating margin
- 7.6%
- Net margin
- 18.7%
- EBITDA margin
- 30.6%
- ROE
- 30.8%
- ROCE
- 5.7%
- ROA
- 10.9%
- Asset turnover
- 0.58
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $8.3B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 0.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 0.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 224.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$10.0M
Solvency
- Current ratio
- 1.23
- Debt / Equity
- 1.00
- Debt / Assets
- 0.35
- CFO / Net profit
- 0.24
- Cash / Market cap
- 6.2%
Where the revenue went
Of every $100 of FY2025 revenue, $19 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $3.9B |
| Revenue | Gross profit | $4.5B |
| Gross profit | Research and development | $739.0M |
| Gross profit | Selling, general and administrative | $3.1B |
| Gross profit | Operating income | $632.0M |
| Operating income | Pretax income | $632.0M |
| Interest and other income | Pretax income | $1.1B |
| Pretax income | Tax and other | $157.0M |
| Pretax income | Net income | $1.6B |
Revenue and net profit
Revenue grew 0.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $8.1B | $1.3B |
| FY2023 | $8.2B | $1.3B |
| FY2024 | $8.3B | $479.0M |
| FY2025 | $8.3B | $1.6B |
Cash flows
FY2025: $369.0M from operations, -$10.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $1.7B | $1.4B |
| FY2023 | $1.9B | $1.6B |
| FY2024 | $1.2B | $805.0M |
| FY2025 | $369.0M | -$10.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $8.3B+0.9%1Y
- EBITDA
- $2.5B+66.9%1Y
- Net profit
- $1.6B+224.8%1Y
- Cash from operations
- $369.0M-68.9%1Y
- Free cash flow
- -$10.0M-101.2%1Y
- Revenue CAGR, 3Y
- 0.8%
- Net profit CAGR, 3Y
- 5.0%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $8.3B | $2.5B | $1.6B | -$10.0M | 30.8% | +0.9% | +224.8% |
Monthly returns
Month-by-month returns of SOLV across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $14.3B |
| Current assets | $3.9B |
| Non-current assets | $10.4B |
| Liabilities | $9.2B |
| Current liabilities | $3.1B |
| Non-current liabilities | $6.1B |
| Equity | $5.0B |
| Paid-in capital | $3.9B |
| Retained earnings | $1.8B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; SOLV highlighted.
P/E against peers
SOLV trades at 9.2x earnings against a peer median of 23.8x (a 61% discount).
Not shown (no positive earnings and no EV / Sales): Viatris Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Solventum CorporationSOLVthis companyP/E ↓ discount | $14.3B | 9.2x | 2.8x | 30.8% | 7.2x |
| Incyte CorporationINCY | $20.2B | 15.7x | 3.9x | 24.9% | 9.8x |
| Viatris Inc.VTRS | $18.5B | — | 1.3x | -23.9% | — |
| Zimmer Biomet Holdings, Inc.ZBH | $16.8B | 23.8x | 1.3x | 5.6% | 10.7x |
| DaVita Inc.DVA | $12.3B | 16.5x | -18.9x | -114.7% | 9.3x |
| The Cooper Companies, Inc.COO | $12.1B | 32.3x | 1.5x | 4.6% | 13.9x |
| Align Technology, Inc.ALGN | $12.1B | 29.4x | 3.0x | 10.1% | 13.5x |
| Insulet CorporationPODD | $10.1B | 41.0x | 6.7x | 16.3% | 21.2x |
| Universal Health Services, Inc.UHS | $8.6B | 5.8x | 1.2x | 20.5% | 5.0x |
| Peer median | — | 23.8x | 1.4x | 7.8% | 10.7x |
Year-to-date ROI
SOLV since 1 January, against earlier years.
Historical volatility
SOLV's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 20.8% |
| FY2023 | 20.0% |
| FY2024 | 12.6% |
| FY2025 | 7.6% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $8.3B |
| Cost of revenueCost Of Revenue | $3.9B |
| Gross profitGross Profit | $4.5B |
| Operating expensesOperating Expense | $3.8B |
| Research and developmentResearch And Development | $739.0M |
| Selling, general and administrativeSelling General And Administration | $3.1B |
| Rent expense supplementalRent Expense Supplemental | — |
| Total expensesTotal Expenses | $7.7B |
| Operating incomeOperating Income | $632.0M |
| Interest and other | |
| Pretax incomePretax Income | $1.7B |
| TaxTax Provision | $157.0M |
| Net incomeNet Income | $1.6B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $14.3B |
| Current assetsCurrent Assets | $3.9B |
| Non-current assetsTotal Non Current Assets | $10.4B |
| LiabilitiesTotal Liabilities Net Minority Interest | $9.2B |
| Current liabilitiesCurrent Liabilities | $3.1B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $6.1B |
| EquityTotal Equity Gross Minority Interest | $5.0B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $369.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $369.0M |
| Net income, continuing operationsNet Income From Continuing Operations | $1.6B |
| Depreciation and amortisationDepreciation And Amortization | $489.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $489.0M |
| Stock-based compensationStock Based Compensation | $161.0M |
| Deferred taxDeferred Tax | -$120.0M |
| Deferred income taxDeferred Income Tax | -$120.0M |
| Operating gains and lossesOperating Gains Losses | -$1.5B |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$1.5B |
| Pension and employee benefit expensePension And Employee Benefit Expense | $62.0M |
| Change in working capitalChange In Working Capital | -$119.0M |
| Other non-cash itemsOther Non Cash Items | -$111.0M |
| Investing cash flowInvesting Cash Flow | $2.8B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $2.8B |
| Capital expenditureCapital Expenditure | -$379.0M |
| Purchase of PP&EPurchase Of PPE | -$379.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$379.0M |
| AcquisitionsPurchase Of Business | -$696.0M |
| DisposalsSale Of Business | $3.9B |
| Net acquisitions and disposalsNet Business Purchase And Sale | $3.2B |
| Sale of investmentsSale Of Investment | — |
| Net investment purchases and salesNet Investment Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | -$18.0M |
| Financing cash flowFinancing Cash Flow | -$3.1B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$3.1B |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$3.1B |
| Net debt issuedNet Issuance Payments Of Debt | -$3.1B |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$3.1B |
| Net long-term debt issuedNet Long Term Debt Issuance | -$3.1B |
| Other financing chargesNet Other Financing Charges | $13.0M |
| Change in cashChanges In Cash | $109.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 700.0% |
| Cash at the start of the yearBeginning Cash Position | $762.0M |
| Cash at the end of the yearEnd Cash Position | $878.0M |
| Free cash flowFree Cash Flow | -$10.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Solventum Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 9.2 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read